Gland Pharma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Srinivas Sadu

Amministratore delegato

₹70.2m

Compenso totale

Percentuale dello stipendio del CEO	95.3%
Mandato del CEO	5.6yrs
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	4.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Nov 07

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Oct 26

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Oct 01

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Sep 05

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 09

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Feb 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Srinivas Sadu rispetto agli utili di Gland Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	₹7b
Jun 30 2024	n/a	n/a	₹7b
Mar 31 2024	₹70m	₹67m	₹8b
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹7b
Mar 31 2023	₹124m	₹61m	₹8b
Dec 31 2022	n/a	n/a	₹10b
Sep 30 2022	n/a	n/a	₹10b
Jun 30 2022	n/a	n/a	₹11b
Mar 31 2022	₹124m	₹61m	₹12b
Dec 31 2021	n/a	n/a	₹12b
Sep 30 2021	n/a	n/a	₹11b
Jun 30 2021	n/a	n/a	₹10b
Mar 31 2021	₹89m	₹31m	₹10b
Dec 31 2020	n/a	n/a	₹9b
Jun 30 2020	n/a	n/a	₹9b
Mar 31 2020	₹59m	₹32m	₹8b
Mar 31 2019	₹23m	n/a	₹5b
Mar 31 2018	₹11m	₹5m	₹3b

Compensazione vs Mercato: La retribuzione totale di Srinivas ($USD 832.26K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 590.32K ).

Compensazione vs guadagni: La retribuzione di Srinivas è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Srinivas Sadu (55 yo)

5.6yrs

Mandato

₹70,150,000

Compensazione

Mr. Srinivas Sadu, B. Pharm, M. S., MBA has been Executive Director and Chief Executive Officer at Gland Pharma Ltd. since April 25, 2019 and serves as its Executive Chairman from June 10, 2024. He had bee...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Srinivas Sadu	CEO & Executive Chairman	5.6yrs	₹70.15m	Nessun dato
Ravi Mitra	Chief Financial Officer	5.2yrs	₹20.45m	Nessun dato
Sampath Pallerlamudi	Company Secretary & Vice-President of Compliance & CSR	no data	₹6.05m	Nessun dato
Satnam Loomba	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Ankit Gupta	Head of Investments	1.2yrs	Nessun dato	Nessun dato
Surinder Koul	Head of Domestic Marketing	less than a year	Nessun dato	Nessun dato
K Rao	Head of Quality	less than a year	Nessun dato	0.0012% ₹ 3.6m
R.V.R. Sastry	Senior Vice President of R&D	no data	Nessun dato	Nessun dato
Rong Wu	Chief Financial Controller	no data	Nessun dato	0.000020% ₹ 57.8k

0.7yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di GLAND non è considerato esperto (durata media 0.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Srinivas Sadu	CEO & Executive Chairman	5.6yrs	₹70.15m	Nessun dato
Naina Lal Kidwai	Independent Director	3.5yrs	₹10.50m	Nessun dato
Udo Vetter	Independent Director	6.8yrs	₹3.00m	Nessun dato
Essaji Vahanvati	Independent Director	4.2yrs	₹3.00m	Nessun dato
Wenjie Zhang	Non-Executive and Non-Independent Director	less than a year	Nessun dato	Nessun dato
Jia Ai Zhang	Non-Independent Non Executive Director	3.5yrs	Nessun dato	Nessun dato
Satyanarayana Chavali	Independent Director	6yrs	₹3.00m	Nessun dato

4.2yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GLAND sono considerati esperti (durata media dell'incarico 4.2 anni).

Gland Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Gland Pharma Limited Announces Chief Executive Officer Changes, Effective from January 15, 2025

Insufficient new directors

Gland Pharma Limited Announces Executive Changes

Gland Pharma Limited Announces Board Changes

Insider recently sold ₹24m worth of stock

Head of Quality recently sold ₹8.3m worth of stock

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Gland Pharma Limited Announces Chief Executive Officer Changes, Effective from January 15, 2025

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Insufficient new directors

Gland Pharma Limited Announces Executive Changes

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Gland Pharma Limited Announces Board Changes

Consensus EPS estimates fall by 16%

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Gland Pharma Limited to Report Q4, 2025 Results on May 20, 2025

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gland Pharma Receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Limited to Report Q1, 2025 Results on Aug 06, 2024

Insider recently sold ₹24m worth of stock

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million

Head of Quality recently sold ₹8.3m worth of stock

Insider recently sold ₹9.2m worth of stock

Gland Pharma Limited Announces Management Changes

Insufficient new directors

Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively

Consensus EPS estimates fall by 14%, revenue upgraded

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Gland Pharma Limited, Annual General Meeting, Aug 30, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q4, 2024 Results on May 22, 2024

Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals

Chief Technical Officer recently sold ₹14m worth of stock

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Chief Operating Officer recently sold ₹2.8m worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

New minor risk - Insider selling

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2024 Results on Nov 06, 2023

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Investor sentiment improves as stock rises 23%

Gland Pharma Limited Appoints Prakash Vithal Baliga as Chief Operating Officer

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 12% to ₹1,520

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Gland Pharma Limited, Annual General Meeting, Aug 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹683k worth of stock

Investor sentiment improves as stock rises 16%

Insider recently sold ₹756k worth of stock

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Price target decreased by 13% to ₹2,119

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q3, 2023 Results on Jan 23, 2023

Insider recently sold ₹798k worth of stock

Insider recently sold ₹869k worth of stock

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2023 Results on Oct 26, 2022

Insider recently sold ₹4.1m worth of stock